Vol 51 No 01

"It’s apparent that reducing overdiagnosis alone may not necessarily reduce over treatment, and that separate and specific focus on prevention of over treatment is still needed," Badar M. Mian, MD, writes.

Almost all clinicians avoided negative fee schedule adjustment in 2022.

Investigators found that mitigation methods such as adding a physical barrier or increasing distance could lessen the harmful effects.

"PCM codes require the practitioner to develop a disease-specific care plan, to obtain a patient’s verbal or written consent, and to educate the patient on PCM," write Jonathan Rubenstein, MD, and Mark Painter.

"In the office, absolutely, I should be called by my profession," says one urologist.

“There is a critical unmet need for efficacious bladder-sparing therapies for patients with BCG-unresponsive bladder cancer,” said Roger Li, MD.

ADT intensification through doublet and triplet regimens has become standard for most patients with metastatic castration-sensitive prostate cancer, Alicia Morgans, MD, MPH, explained in a presentation at the 2022 LUGPA Annual Meeting.

The co-primary end points have been achieved in the phase 3 ZIRCON trial exploring the novel PET imaging radiopharmaceutical TLX250-CDx in clear cell renal cell carcinoma.

64Cu SAR-Bombesin targets the Gastrin Releasing Peptide receptor, which is found on prostate tumors as well as several other tumors.

John Myrga, MD, discusses recent findings on levels of pain, anxiety, and embarrassment for patients undergoing a prostate biopsy with a transperineal approach versus a transrectal approach.

The FDA has updated the label for mitomycin-containing reverse thermal gel (Jelmyto) in low-grade upper-tract urothelial cancer by extending the in-use period for pyelocalyceal solution admixture.